SCHEMBL6717705

SCHEMBL6717705

Cc1ccccc1NC(=O)C(C)N(S)C(=O)NC(C(=O)O)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
PGR P06401 1/20 0.42
SCN1A P35498 1/20 0.42
SCN2A Q99250 1/20 0.42
SCN3A Q9NY46 1/20 0.42
LMNA P02545 3/20 0.41
MAPT P10636 3/20 0.41
HPGD P15428 3/20 0.41
GAA P10253 2/20 0.41
ALOX12 P18054 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
ANPEP P15144 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6543095 0.80 FPR2 (0.56) HTTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL6727015 0.76 CYP1A2 (0.53) HTTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL6717435 0.74 KMT2A (0.46) CYP2D6CYP2C9CYP2C19LMNAMAPT
SCHEMBL6715799 0.73 CYP1A2 (0.53) HTTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL28920385 0.72 POLB (0.56) HTTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL28577403 0.71 HTT (0.55) HTTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL2483409 0.71 RAB9A (0.48) HTTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL14842465 0.71 RAB9A (0.58) HTTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL8337352 0.70 CTSS (0.60) HTTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL8348009 0.70 CTSS (0.60) HTTCYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 HTT 272/4885CYP1A2 405/4885CYP3A4 591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.